Bloomberg News

Clal Biotechnology Says Teva Investment in Curetech Completed

October 02, 2011

Oct. 2 (Bloomberg) -- Clal Biotechnology Industries Ltd. said that Teva Pharmaceutical Industries Ltd.’s investment in CureTech Ltd. was completed, leaving Clal with 12 percent of Curetech. Clal Biotechnology made the announcement to the Tel Aviv Stock Exchange today.

To contact the reporter on this story: Gwen Ackerman in Jerusalem at gackerman@bloomberg.net

To contact the editor responsible for this story: Alisa Odenheimer at aodenheimer@bloomberg.net


Race, Class, and the Future of Ferguson
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus